Burkitt's Lymphoma
1982; Wiley; Volume: 32; Issue: 3 Linguagem: Inglês
10.3322/canjclin.32.3.144
ISSN1542-4863
Autores Tópico(s)Chronic Lymphocytic Leukemia Research
ResumoCA: A Cancer Journal for CliniciansVolume 32, Issue 3 p. 144-161 ArticleFree Access Burkitt's lymphoma John L. Ziegler M.D., John L. Ziegler M.D. Associate Chief of Staf for Education of Veterans Administration Medical Center in San Francisco, CaliforniaSearch for more papers by this author John L. Ziegler M.D., John L. Ziegler M.D. Associate Chief of Staf for Education of Veterans Administration Medical Center in San Francisco, CaliforniaSearch for more papers by this author First published: May/June 1982 https://doi.org/10.3322/canjclin.32.3.144Citations: 4AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958; 46: 218– 23. 2 Burkitt DP, O'Conor GT. Malignant lymphoma in African children. I. A clinical syndrome. Cancer. 1961; 14: 258– 69. 3 O'Conor GT. Malignant lymphoma in African children. II. A pathological entity. Cancer. 1961; 14: 270– 83. 4 Burkitt D. Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer. 1967; 20: 756– 9. 5 Ngu VA. The treatment of Burkitt tumour. West Afr Med J. 1968; 17: 273– 80. 6 Clifford P, Singh S, Stjernswärd J, et al. Long-term survival of patients with Burkitt's lymphoma: an assessment of treatment and other factors which may relate to survival. Cancer Res. 1967; 27: 2578– 615. 7 Burkitt DP. Clinical evidence suggesting the development of an immunological response against African lymphoma. In: UICC Symposium on the treatment of Burkitt's tumor. New York: Springer-Verlag, 1967: 197– 203. 8 Burkitt D. Determining the climatic limitations of a children's cancer common in Africa. Br Med J. 1962; 2: 1019– 23. 9 Burkitt D. A children's cancer development dependent upon climatic factors. Nature. 1962: 194: 232– 4. 10 Haddow AJ. Epidemiological evidence suggesting an infective element in the aetiology. In: DP Burkitt, DH Wright, eds. Burkitt's lymphoma. Edinburgh: Churchill Livingstone, 1970; 198– 209. 11 Burchenal JH. Geographic chemotherapy—Burkitt's tumor as a stalking horse for leukemia: presidential address. Cancer Res. 1966; 26: 2393– 405. 12 Broder S, Uchiyama T, Waldmann TA. Neoplasms of immunoregulatory cells. Am J Clin Pathol. 1979; 72: 724– 31. 13 Magrath IT. Lymphocyte differentiation: an essential basis for the comprehension of lymphoid neoplasia. J Natl Cancer Inst. (in press). 14 Berard CW, Greene MK, Jaffe ES, et al. A multidisciplinary approach to understanding non-Hodgkin's lymphomas. Ann Intern Med. 1981; 94: 218– 35. 15 Lukes RJ, Collins RD. New approaches to the classification of the lymphomata. Br J Cancer. 1975; 31: Suppl 2: 1– 28. 16 Schwartz RS. Immunoregulation, oncogenic viruses, and malignant lymphomas. Lancet. 1972; 1: 1266– 9. 17 Mann RB, Jaffe ES, Braylan RC, et al. Nonendemic Burkitt's lymphoma: a B-cell tumor related to germinal centers. N Engl J Med. 1976; 295: 685– 91. 18 Berard C, O'Conor GT, Thomas LB, et al. Histopathological definitions of Burkitt's tumour. Bull WHO. 1969; 40: 601– 7. 19 Vogler LB, Crist WM, Bockman DE, et al. Pre-B-cell leukemia: a new phenotype of childhood lymphoblastic leukemia. N Engl J Med. 1978; 298: 872– 8. 20 Warnke R, Miller R, Grogan T, et al. Immunologic phenotype in 30 patients with diffuse large-cell lymphoma. N Engl J Med. 1980; 303: 293– 300. 21 Jaffe ES, Berard CW. Lymphoblastic lymphoma, a term rekindled with new precision. Ann Intern Med. 1978; 89: 415– 7. 22 DeVita VT Jr. Human models of human diseases: breast cancer and the lymphomas. Int J Radiat Oncol Biol Phys. 1979; 5: 1855– 67. 23 Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964; 1: 702– 3. 24 Ziegler JL, Magrath IT, Gerber P, et al. Epstein-Barr virus and human malignancy. Ann Intern Med. 1977; 86: 323– 36. 25 Klein G. The Epstein-Barr virus and neoplasia. N Engl J Med. 1975; 293: 1353– 7. 26 Henle G, Henle W, Clifford P, et al. Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst. 1969; 43: 1147– 57. 27 Lindahl T, Klein G, Reedman BM, et al. Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear anTIGen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer. 1974; 13: 764– 72. 28 Olweny CLM, Atine I, Kaddu-Mukasa A, et al. Epstein-Barr virus genome studies in Burkitt's and non-Burkitt's lymphomas in Uganda. J Natl Cancer Inst. 1977; 58: 1191– 6. 29 Evans AS, Niederman JC, McCollum RW. Seroepidemiologic studies of infectious mononucleosis with EB virus. N Engl J Med. 1968; 279: 1121– 7. 30 de-Thé G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature. 1978; 274: 756– 61. 31 Biggar RJ, Henle W, Fleisher G, et al. Primary Epstein-Barr virus infections in African infants. I. Decline of maternal antibodies and time of infection. Int J Cancer. 1978; 22: 239– 43. 32 Biggar RJ, Henle G, Böcker J, et al. Primary Epstein-Barr virus infections in African infants. II. Clinical and serological observations during seroconversion. Int J Cancer. 1978; 22: 244– 50. 33 Jondal M, Klein G, Oldstone MBA, et al. Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scand J Immunol. 1976; 5: 401– 10. 34 Nilsson K, Klein G, Henle W, et al. The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer. 1971; 8: 443– 50. 35 Shope T, Dechairo D, Miller G. Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus. Proc Natl Acad Sci USA. 1973; 70: 2487– 91. 36 zur Hausen H, Schulte-Holthausen H, Klein E, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 1970; 228: 1056– 8. 37 Henle W, Henle G, Ho H-C, et al. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst. 1970; 44: 225– 31. 38 Ziegler JL, Andersson M, Klein G, et al. Detection of Epstein-Barr virus DNA in American Burkitt's lymphomas. Int J Cancer. 1976; 17: 701– 6. 39 Klein G. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Acad Sci USA. 1979; 76: 2442– 6. 40 Tosato G, Magrath I, Koski I, et al. Activation of suppressor T cells during Epstein-Barr-virus-induced infectious mononucleosis. N Engl J Med. 1979; 301: 1133– 7. 41 Kaiser-McCaw B, Epstein AL, Kaplan HS, et al. Chromosome 14 translocation in African and North American Burkitt's lymphoma. Int J Cancer. 1977; 19: 482– 6. 42 Douglass EC, Magrath IT, Lee EC, et al. Cytogenetic studies in non-African Burkitt lymphoma. Blood. 1980; 55: 148– 55. 43 Siemiatycki J, Brubaker G, Geser A. Space-time clustering of Burkitt's lymphoma in East Africa: analysis of recent data and a new look at old data. Int J Cancer. 1980; 25: 197– 203. 44 Henle W, Henle G, Gunvén P, et al. Patterns of antibodies to Epstein-Barr virus-induced early anTIGens in Burkitt's lymphoma: comparison of dying patients with long-term survivors. J Natl Cancer Inst. 1973; 50: 1163– 73. 45 Pearson GR, Qualtiere LF, Klein G, et al. Epstein-Barr virus-specific antibody-dependent cellular cytotoxicity in patients with Burkitt's lymphoma. Int J Cancer. 1979; 24: 402– 6. 46 Magrath IT. Immunosuppression in Burkitt's lymphoma. I. Cutaneous reactivity to recall anTIGens: alterations induced by a tumour burden and by BCG administration. Int J Cancer. 1974; 13: 839– 49. 47 Magrath IT, Simon RM. Immunosuppression in Burkitt's lymphoma. II. Peripheral blood lymphocyte populations related to clinical status. Int J Cancer. 1976; 18: 399– 408. 48 Heimer R, Klein G. Circulating immune complexes in sera of patients with Burkitt's lymphoma and nasopharyngeal carcinoma. Int J Cancer. 1976; 18: 310– 6. 49 de-Thé G. Is Burkitt's lymphoma related to perinatal infection by Epstein-Barr virus? Lancet. 1977; 1: 335– 8. 50 Purtilo DT, Szymanski I, Bhawan J, et al. Epstein-Barr virus infections in the X-linked recessive lymphoproliferative syndrome. Lancet. 1978; 1: 798– 801. 51 Purtilo DT. Epstein-Barr-virus-induced oncogenesis in immune-deficient individuals. Lancet. 1980; 1: 300– 3. 52 Purtilo DT. X-linked lymphoproliferative syndrome: an immunodeficiency disorder with acquired agammaglobulinemia, fatal infectious mononucleosis, or malignant lymphoma. Arch Pathol Lab Med. 1981; 105: 119– 21. 53 Robinson JE, Brown N, Andiman W, et al. Diffuse polyclonal B-cell lymphoma during primary infection with Epstein-Barr virus. N Engl J Med. 1980; 302: 1293– 7. 54 Burkitt DP. Etiology of Burkitt's lymphoma—an alternative hypothesis to a vectored virus. J Natl Cancer Inst. 1969; 42: 19– 28. 55 O'Conor GT. Persistent immunologic stimulation as a factor in oncogenesis, with special reference to Burkitt's tumor. Am J Med. 1970; 48: 279– 85. 56 Kafuko GW, Baingana N, Knight EM, et al. Association of Burkitt's tumour and holoendemic malaria in West Nile district, Uganda: malaria as a possible aetiologic factor. East Afr Med J. 1969; 46: 414– 36. 57 Greenwood BM. Possible role of a B-cell mitogen in hypergammaglobulinaemia in malaria and trypanosomiasis. Lancet. 1974; 1: 435– 6. 58 Schwartz RS. Epstein-Barr virus—oncogen or mitogen?, editorial. N Engl J Med. 1980; 302: 1307– 8. 59 Kufe D, Magrath IT, Ziegler JL, et al. Burkitt's tumors contain particles encapsulating RNA-instructed DNA polymerase and high molecular weight virus-related RNA. Proc Natl Acad Sci USA. 1973; 70: 737– 41. 60 Yaniv A, Gotlieb-Stematsky T, Vonsover A, et al. Evidence for type-C retrovirus production by Burkitt's lymphoma-derived cell line. Int J Cancer. 1980; 25: 205– 11. 61 Pizzo PA, Magrath IT, Chattopadhyay SK, et al. A new tumour-derived transforming strain of Epstein-Barr virus. Nature. 1978; 272: 629– 31. 62 Dambaugh T, Raab-Traub N, Heller M, et al. Variations among isolates of Epstein-Barr virus. Ann NY Acad Sci. 1980; 354: 309– 25. 63 Brubaker G, Levin AG, Steel CM, et al. Multiple cases of Burkitt's lymphoma and other neoplasms in families in the North Mara district of Tanzania. Int J Cancer. 1980; 26: 165– 70. 64 Lewin KJ, Kahn LB, Novis BH. Primary intestinal lymphoma of "Western" and "Mediterranean" type, alpha chain disease and massive plasma cell infiltration: a comparative study of 37 cases. Cancer. 1976; 38: 2511– 28. 65 Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977; 50: 481– 92. 66 Wright DH. Gross distribution and haematology. In: DP Burkitt, DH Wright, eds. Burkitt's lymphoma. Edinburgh: Churchill Livingstone, 1970: 64– 81. 67 Ziegler JL, Bluming AZ, Morrow RH, et al. Central nervous system involvement in Burkitt's lymphoma. Blood. 1970; 36: 718– 28. 68 Ziegler JL, Bluming AZ. Intrathecal chemotherapy in Burkitt's lymphoma. Br Med J. 1971; 3: 508– 12. 69 Levine PH, Cho BR, Connelly RR, et al. The American Burkitt Lymphoma Registry: a progress report. Ann Intern Med. 1975; 83: 31– 6. 70 Arseneau JC, Canellos GP, Banks PM, et al. American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. Am J Med. 1975; 58: 314– 21. 71 Banks PM, Arseneau JC, Gralnick HR, et al. American Burkitt's lymphoma: a clinicopathologic study of 30 cases. II. Pathologic correlations. Am J Med. 1975; 58: 322– 9. 72 Ziegler JL. Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience. N Engl J Med. 1977; 297: 75– 80. 73 Magrath IT, Pizzo PA, Whang-Peng J, et al. Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear anTIGen. I. Physical, cytogenetic, and growth characteristics. J Natl Cancer Inst. 1980; 64: 465– 76. 74 Magrath IT, Freeman CB, Pizzo P, et al. Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear anTIGen. II. Surface markers. J Natl Cancer Inst. 1980; 64: 477– 83. 75 Iversen OH, Iversen U, Ziegler JL, et al. Cell kinetics in Burkitt lymphoma. Eur J Cancer. 1974; 10: 155– 63. 76 Chabner BA, Fisher R, Young RC, et al. Staging of non-Hodgkin's lymphoma. Semin Oncol. 1980; 7: 285– 91. 77 Murphy SB. Classification, staging, and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980; 7: 322– 9. 78 Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Classification. Cancer Res. 1971; 31: 1860– 1. 79 Ziegler JL, Magrath IT. Burkitt's lymphoma. Pathobiol Annu. 1974; 4: 129– 42. 80 Wollner N, Burchenal JH, Lieberman PH, et al. Non-Hodgkin's lymphoma in children: a comparative study of two modalities of therapy. Cancer. 1976; 37: 123– 34. 81 Magrath I, Lee YJ, Anderson T, et al. Prognostic factors in Burkitt's lymphoma: importance of total tumor burden. Cancer. 1980; 45: 1507– 15. 82 Magrath IT, Lwanga S, Carswell W, et al. Surgical reduction of tumour bulk in management of abdominal Burkitt's lymphoma. Br Med J. 1974; 2: 308– 12. 83 Norin T, Clifford P, Einhorn J, et al. Conventional and superfractionated radiation therapy in Burkitt's lymphoma. Acta Radiol. 1971; 10: 545– 57. 84 Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma. Cancer. 1980; 45: 630– 7. 85 Carabell SC, Cassady JR, Weinstein HJ, et al. The role of radiation therapy in the treatment of pediatric non-Hodgkin's lymphomas. Cancer. 1978; 42: 2193– 205. 86 Morrow RH, Pike MC, Kisuule A. Survival of Burkitt's lymphoma patients in Mulago Hospital, Uganda. Br Med J. 1967; 4: 323– 7. 87 Ziegler JL, Morrow RH Jr, Fass L, et al. Treatment of Burkitt's lymphoma with cyclophosphamide. Cancer. 1970; 26: 474– 84. 88 Ziegler JL. Chemotherapy of Burkitt's lymphoma. Cancer. 1972; 30: 1534– 40. 89 Ziegler JL, Magrath IT, Olweny CLM. Cure of Burkitt's lymphoma: 10-year follow-up of 157 Ugandan patients. Lancet. 1979; 2: 936– 8. 90 Cohen LF, Balow JE, Magrath IT, et al. Acute tumor-lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med. 1980; 68: 486– 91. 91 Olweny CLM, Katongole-Mbidde E, Kaddu-Mukasa A, et al. Treatment of Burkitt's lymphoma: randomized clinical trial of single agent versus combination chemotherapy. Int J Cancer. 1976; 17: 436– 40. 92 Nkrumah FK, Perkins IV, Biggar RJ. Combination chemotherapy in abdominal Burkitt's lymphoma. Cancer. 1977; 40: 1410– 6. 93 Olweny CLM, Atine I, Kaddu-Mukasa A, et al. Cerebrospinal irradiation of Burkitt's lymphoma: failure in preventing central nervous system relapse. Acta Radiol. 1977; 16: 225– 31. 94 Ziegler JL, Magrath IT, Nkrumah FK, et al. Evaluation of CCNU (NSC-79037) used for the prevention of CNS involvement in Burkitt's lymphoma. Cancer Treat Rep. 1975; 59: 1155– 6. 95 Magrath IT, Spiegel RJ, Edwards BK, et al. Improved results of chemotherapy in young patients with Burkitt's (BL), undifferentiated (UL), and lymphoblastic lymphomas (LL). Proc Am Assoc Cancer Res Am Soc Clin Oncol. 1981; 22: 520. abstract. 96 Ziegler JL, Magrath IT, Deisseroth AB, et al. Combined modality treatment of Burkitt's lymphoma. Cancer Treat Rep. 1978; 62: 2031– 4. 97 Ziegler JL, Bluming AZ, Fass L, et al. Relapse patterns in Burkitt's lymphoma. Cancer Res. 1972; 32: 1267– 72. 98 Nkrumah FK, Perkins IV. Relapse in Burkitt's lymphoma. Int J Cancer. 1976; 17: 455– 60. 99 Biggar JR, Nkrumah FK, Henle W, et al. Very late relapses in patients with Burkitt's lymphoma: clinical and serologic studies. J Natl Cancer Inst. 1981; 66: 439– 44. 100 Olweny CLM, Katongole-Mbidde E, Otim D, et al. Long-term experience with Burkitt's lymphoma in Uganda. Int J Cancer. 1980; 26: 261– 6. 101 Fialkow PJ, Klein E, Klein G, et al. Immunoglobulin and glucose-6-phosphate dehydrogenase as markers of cellular ORIGIN in Burkitt lymphoma. J Exp Med. 1973; 138: 89– 102. 102 Nkrumah FK, Henle W, Henle G, et al. Burkitt's lymphoma: its clinical course in relation to immunologic reactivities to Epstein-Barr virus and tumor-related anTIGens. J Natl Cancer Inst. 1976; 57: 1051– 6. 103 Ziegler JL, Bluming AZ, Magrath IT, et al. Intensive chemotherapy in patients with generalized Burkitt's lymphoma. Int J Cancer. 1972; 10: 254– 61. 104 Arseneau JC, Bagley CM, Anderson T, et al. Hyperkalemia, a sequel to chemotherapy of Burkitt's lymphoma. Lancet. 1973; 1: 10– 4. 105 Shackney SE, McCormack GW, Cuchural GJ Jr. Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. Ann Intern Med. 1978; 89: 107– 21. 106 Young RC, Canellos GP, Chabner BA, et al. Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet. 1973; 1: 1339– 43. 107 Erickson LC, Laurent G, Sharkey NA, et al. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumor cells. Nature. 1980; 288: 727– 9. 108 Appelbaum FR, Deisseroth AB, Graw RG Jr, et al. Prolonged complete remission following high-dose chemotherapy of Burkitt's lymphoma in relapse. Cancer. 1978; 41: 1059– 63. 109 Fass L, Herberman RB. Evaluation of complement-dependent human cytotoxic antibody reactive with Burkitt's lymphoma biopsy cells. Proc Soc Exp Biol Med. 1970; 133: 286– 9. 110 Bluming AZ, Ziegler JL, Fass L, et al. Delayed cutaneous sensitivity reactions to autologous Burkitt lymphoma protein extracts: results of a prospective two and a half year study. Clin Exp Immunol. 1971; 9: 713– 9. 111 Gunvén P, Klein G, Onyango J, et al. Antibodies associated with Epstein-Barr virus in Burkitt's lymphoma during injection of BCG or irradiated antochthonous tumor cells. J Natl Cancer Inst. 1973; 51: 45– 56. 112 Magrath IT, Ziegler JL. Failure of BCG immunostimulation to affect the clinical course of Burkitt's lymphoma. Br Med J. 1976; 1: 615– 8. 113 Gunvén P, Klein G, Ziegler JL, et al. Epstein-Barr virus-associated and other antiviral antibodies during intense BCG administration to patients with Burkitt's lymphoma in remission. J Natl Cancer Inst. 1978; 60: 31– 7. 114 Jose DG, Seshadri R. Circulating immune complexes in human neuroblastoma: direct assay and role in blocking specific cellular immunity. Int J Cancer. 1974; 13: 824– 38. 115 Rhodes J. Altered expression of human monocyte Fc receptors in malignant disease. Nature. 1977; 265: 253– 5. 116 Grosser N, Thomson DMP. Tube leukocyte (monocyte) adherence inhibition assay for the detection of antitumour immunity. III. "Blockade" of monocyte reactivity by excess free anTIGen and immune complexes in advanced cancer patients. Int J Cancer. 1976; 18: 58– 66. 117 SE Salmon, ed. Cloning of human tumor stem cells. New York: Alan R Liss, 1980: 315– 27. 118 Shultz RM. Factors limiting tumoricidal function of interferon-induced effector systems, activated macrophages and natural killer cells. Cancer Immunol Immunother. 1981; 10: 61– 6. 119 Terman DS, Stewart I, Robinette J, et al. Specific removal of DNA antibodies in vivo with an extracorporeal immunoadsorbent. Clin Exp Immunol. 1976; 24: 231– 7. 120 Bansal SC, Bansal BR, Thomas HL, et al. Ex vivo removal of serum IgG in a patient with colon carcinoma: some biochemical, immunological, and histological observations. Cancer. 1978; 42: 1– 18. 121 Magrath IT, Freeman C, Novikovs L. Induction of complement receptor expression in cell lines derived from human undifferentiated lymphomas. I. Mode of action of theophylline and inhibition by certain purines. J Immunol. (in press). Citing Literature Volume32, Issue3May/June 1982Pages 144-161 ReferencesRelatedInformation
Referência(s)